Search

Your search keyword '"Beygui, Farzin"' showing total 728 results
Start Over Author "Beygui, Farzin"
728 results on '"Beygui, Farzin"'

1. Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome

Author

Manzo-Silberman, Stéphane, Guedeney, Paul, Cayla, Guillaume, Beygui, Farzin, Rangé, Grégoire, Motovska, Zuzana, Procopi, Niki, Kerneis, Mathieu, Zeitouni, Michel, El Kasty, Mohamad, Teiger, Emmanuel, Filippi, Emmanuelle, Coste, Pierre, Huchet, François, Cottin, Yves, Karasek, Jiří, Arnould, Marc-Antoine, Braik, Nassim, Barthelemy, Olivier, Portal, Jean-Jacques, Vicaut, Eric, Montalescot, Gilles, and Silvain, Johanne

Published
2024
Full Text
View/download PDF

3. P2Y12 Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis

Author

Roule, Vincent, Beygui, Farzin, Cayla, Guillaume, Rangé, Grégoire, Motovska, Zuzana, Delarche, Nicolas, Jourda, François, Goube, Pascal, Guedeney, Paul, Zeitouni, Michel, El Kasty, Mohamad, Laredo, Mikael, Dumaine, Raphaëlle, Ducrocq, Gregory, Derimay, François, Van Belle, Eric, Manigold, Thibaut, Cador, Romain, Combaret, Nicolas, Vicaut, Eric, Montalescot, Gilles, and Silvain, Johanne

Published
2024
Full Text
View/download PDF

5. The France PCI registry: Design, methodology and key findings

Author

Rangé, Grégoire, Motreff, Pascal, Benamer, Hakim, Commeau, Philippe, Cayla, Guillaume, Chassaing, Stephan, Laure, Christophe, Monsegu, Jacques, Van Belle, Eric, Py, Antoine, Amabile, Nicolas, Beygui, Farzin, Honton, Benjamin, Lhermusier, Thomas, Boiffard, Emmanuel, Boueri, Ziad, Lhoest, Nicolas, Deharo, Pierre, Adjedj, Julien, Pouillot, Christophe, Pereira, Bruno, Koning, René, and Collet, Jean-Philippe

Published
2023
Full Text
View/download PDF

6. Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve

Author

Eltchaninoff, Hélène, Bellien, Jérémy, Bertrand, Benjamin, Beygui, Farzin, Béziau-Gasnier, Delphine, Brakenhielm, Ebba, Caligiuri, Giuseppina, Chevreul, Karine, Debroucker, Frédérique, Durand, Eric, Fraschini, Christophe, Gilard, Martine, Iung, Bernard, Kamel, Said, Laschet, Jamila, Manrique, Alain, Messas, Emmanuel, Messika-Zeitoun, David, Pinet, Florence, Richard, Vincent, Saloux, Eric, Thoenes, Martin, Tribouilloy, Christophe, Vézier, Claire, Candellier, Alexandre, Issa, Nervana, Grissi, Maria, Brouette, Théo, Avondo, Carine, Gomila, Cathy, Blot, Gérémy, Gubler, Brigitte, Touati, Gilles, Bennis, Youssef, Caus, Thierry, Brazier, Michel, Choukroun, Gabriel, Kamel, Saïd, Boudot, Cédric, and Hénaut, Lucie

Published
2023
Full Text
View/download PDF

9. In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease

Author

Landolff, Quentin, primary, Quillot, Marine, additional, Picard, Fabien, additional, Henry, Patrick, additional, Sideris, Georgios, additional, Bizeau, Olivier, additional, Piot, Christophe, additional, Jouve, Bernard, additional, Rischner, Jérôme, additional, Mejri, Mourad, additional, Charmasson, Claude, additional, Lasserre, Raphael, additional, Pouliquen, Hervé, additional, Joseph, Thierry, additional, Monsegu, Jacques, additional, Karsenty, Bernard, additional, Martin Yuste, Victoria, additional, Richet, Nicolas, additional, Lapeyre, Guy, additional, Beverelli, Fabrizio, additional, Beygui, Farzin, additional, and Koning, René, additional

Published
2023
Full Text
View/download PDF

10. Early survival after acute myocardial infarction with ST-segment elevation: What could be improved? Insights from France PCI French registry

Author

Duband, Benjamin, Motreff, Pascal, Marcollet, Pierre, Gamet, Alexandre, Decomis, Marie-Pascale, Bar, Olivier, Saint Etienne, Christophe, Hakim, Radwan, Canville, Alexandre, Viallard, Louis, BeyguI, Farzin, Lesault, Pierre Francois, Bonnet, Philippe, Durand, Eric, Boiffard, Emmanuel, Collet, Jean-Philippe, Benamer, Hakim, Commeau, Philippe, Cayla, Guillaume, Pereira, Bruno, Koning, Rene, and Rangé, Gregoire

Published
2022
Full Text
View/download PDF

12. Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial.

Author

Durand, Eric, Beziau-Gasnier, Delphine, Michel, Morgane, Iung, Bernard, Tchetche, Didier, Bonnet, Guillaume, Lhermusier, Thibault, Gilard, Martine, Souteyrand, Geraud, Bouleti, Claire, Ohlmann, Patrick, Lefevre, Thierry, Beygui, Farzin, Chassaing, Stephan, Chevreul, Karine, Eltchaninoff, Hélène, II, FAST-TAVI, and investigators, STOP-AS

Subjects
HEART valve prosthesis implantation, AORTIC stenosis, HOSPITAL admission & discharge
Abstract

Background and Aims The length of stay (LOS) after transcatheter aortic valve implantation (TAVI) remains extremely variable whereas early discharge has been shown to be feasible and safe. The study objective was to evaluate the efficacy and safety of an intervention aimed at reducing LOS after transfemoral TAVI. Methods FAST-TAVI II is a prospective, multicentre, cluster, randomized, controlled study including patients with severe symptomatic aortic stenosis, who had transfemoral TAVI. The intervention consisted in a dedicated training programme to implement 10 quality of care measures to reduce LOS with an implementation phase of eight weeks. The primary endpoint was the proportion of patients discharged early within 3 days. Secondary endpoints included: LOS, 30-day mortality and 30-day incidence of readmission for cardiovascular events. Results During the study period, 969 patients were enrolled in the intervention group and 860 patients in the control group. Mean age was 81.9 ± 6.6 years and mean EuroSCORE II was 4.4 ± 4.5%. Early discharge was achieved in 563 (58.1%) patients in the intervention group vs. 364 (42.3%) patients in the control group (P <.0001). Median LOS was significantly reduced in the intervention group compared to the control group [3 (IQR: 3) vs. 4 days (IQR: 3), P <.0001]. Thirty-day mortality was low and similar in the two groups (0.5% vs. 0.9%, P =.30), as were 30-day readmissions (4.6% vs. 2.8%, P =.28). Conclusions The intervention was simple and fast to implement, and was effective and safe to reduce LOS and increase the proportion of patients discharged early after TAVI (NCT04503655). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. P2Y12 inhibitor loading time before elective PCI and the prevention of myocardial necrosis

Author

Roule, Vincent, primary, Beygui, Farzin, additional, Cayla, Guillaume, additional, Range, Grégoire, additional, Motovska, Zuzana, additional, Delarche, Nicolas, additional, Jourda, François, additional, Goube, Pascal, additional, Guedeney, Paul, additional, Zeitouni, Michel, additional, El Kasty, Mohamad, additional, Laredo, Mikael, additional, Dumaine, Raphaëlle, additional, Ducrocq, Gregory, additional, Derimay, François, additional, Van Belle, Eric, additional, Manigold, Thibaut, additional, Cador, Romain, additional, Combaret, Nicolas, additional, Vicaut, Eric, additional, Montalescot, Gilles, additional, and Silvain, Johanne, additional

Published
2023
Full Text
View/download PDF

17. Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study

Author

Hauguel-Moreau, Marie, Guedeney, Paul, Dauphin, Claire, Auffret, Vincent, Marijon, Eloi, Aldebert, Philippe, Clerc, Jean-Michel, Beygui, Farzin, Elbaz, Meyer, Khalil, Wissam Abi, Da Costa, Antoine, Macia, Jean-Christophe, Elhadad, Simon, Cayla, Guillaume, Brugier, Delphine, Silvain, Johanne, Hammoudi, Nadjib, Duthoit, Guillaume, Vicaut, Eric, and Montalescot, Gilles

Abstract

Graphical AbstractDesign of the AFLOAT trial; AA: atrial arrhythmia; ICM = insertable cardiac monitor; od = once a day; PFO = patent foramen ovale; SR = sustained-release.

Published
2024
Full Text
View/download PDF

18. Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.

Author

Lattuca, Benoit, Mazeau, Cedric, Cayla, Guillaume, Ducrocq, Grégory, Guedeney, Paul, Laredo, Mikael, Dumaine, Raphaëlle, El Kasty, Mohamad, Kala, Petr, Nejjari, Mohammed, Hlinomaz, Ota, Morel, Olivier, Varenne, Olivier, Leclercq, Florence, Payot, Laurent, Spaulding, Christian, Beygui, Farzin, Rangé, Grégoire, Motovska, Zuzana, and Portal, Jean-Jacques

Abstract

Whether ticagrelor in chronic coronary syndrome patients undergoing complex percutaneous coronary intervention (PCI) can prevent cardiovascular events is unknown. The authors sought to evaluate outcomes of complex PCI and the efficacy of ticagrelor vs clopidogrel in stable patients randomized in the ALPHEUS (Assessment of Loading with the P2Y 12 inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting) trial. All PCI procedures were blindly reviewed and classified as complex if they had at least 1 of the following criteria: stent length >60 mm, 2-stent bifurcation, left main, bypass graft, chronic total occlusion, use of atherectomy or guiding catheter extensions, multiwire technique, multiple stents. The primary endpoint was a composite of type 4a or b myocardial infarction (MI) and major myocardial injury during the 48 hours after PCI. We compared the event rates according to the presence or not of complex PCI criteria and evaluated the interaction with ticagrelor or clopidogrel. Among the 1,866 patients randomized, 910 PCI (48.3%) were classified as complex PCI. The primary endpoint was more frequent in complex PCI (45.6% vs 26.6%; P < 0.001) driven by higher rates of type 4 MI and angiographic complications (12.2% vs 4.8 %; P < 0.001 and 19.3% vs 8.6%; P < 0.05, respectively). The composite of death, MI, and stroke at 48 hours (12.7% vs 5.1 %; P < 0.05) and at 30 days (13.4% vs 5.3%; P < 0.05) was more frequent in complex PCI. No interaction was found between PCI complexity and the randomized treatment for the primary endpoint (P interaction = 0.47) nor the secondary endpoints. In chronic coronary syndrome, patients undergoing a complex PCI have higher rates of periprocedural and cardiovascular events that are not reduced by ticagrelor as compared with clopidogrel. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve

Author

Candellier, Alexandre, primary, Issa, Nervana, additional, Grissi, Maria, additional, Brouette, Théo, additional, Avondo, Carine, additional, Gomila, Cathy, additional, Blot, Gérémy, additional, Gubler, Brigitte, additional, Touati, Gilles, additional, Bennis, Youssef, additional, Caus, Thierry, additional, Brazier, Michel, additional, Choukroun, Gabriel, additional, Tribouilloy, Christophe, additional, Kamel, Saïd, additional, Boudot, Cédric, additional, Hénaut, Lucie, additional, Eltchaninoff, Hélène, additional, Bellien, Jérémy, additional, Bertrand, Benjamin, additional, Beygui, Farzin, additional, Béziau-Gasnier, Delphine, additional, Brakenhielm, Ebba, additional, Caligiuri, Giuseppina, additional, Chevreul, Karine, additional, Debroucker, Frédérique, additional, Durand, Eric, additional, Fraschini, Christophe, additional, Gilard, Martine, additional, Iung, Bernard, additional, Kamel, Said, additional, Laschet, Jamila, additional, Manrique, Alain, additional, Messas, Emmanuel, additional, Messika-Zeitoun, David, additional, Pinet, Florence, additional, Richard, Vincent, additional, Saloux, Eric, additional, Thoenes, Martin, additional, and Vézier, Claire, additional

Published
2023
Full Text
View/download PDF

20. Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study

Author

Collet, Jean-Philippe, Cayla, Guillaume, Ennezat, Pierre-Vladimir, Leclercq, Florence, Cuisset, Thomas, Elhadad, Simon, Henry, Patrick, Belle, Loic, Cohen, Ariel, Silvain, Johanne, Barthelemy, Olivier, Beygui, Farzin, Diallo, Abdourahmane, Vicaut, Eric, and Montalescot, Gilles

Published
2018
Full Text
View/download PDF

23. P2Y12Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis

Author

Roule, Vincent, Beygui, Farzin, Cayla, Guillaume, Rangé, Grégoire, Motovska, Zuzana, Delarche, Nicolas, Jourda, François, Goube, Pascal, Guedeney, Paul, Zeitouni, Michel, El Kasty, Mohamad, Laredo, Mikael, Dumaine, Raphaëlle, Ducrocq, Gregory, Derimay, François, Van Belle, Eric, Manigold, Thibaut, Cador, Romain, Combaret, Nicolas, Vicaut, Eric, Montalescot, Gilles, and Silvain, Johanne

Abstract

There are dated and conflicting data about the optimal timing of initiation of P2Y12inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y12inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y12Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI.

Published
2024
Full Text
View/download PDF

26. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis

Author

Valgimigli, Marco, Smits, Pieter C, Frigoli, Enrico, Bongiovanni, Dario, Tijssen, Jan, Hovasse, Thomas, Mafragi, Al, Ruifrok, Willem Theodoor, Karageorgiev, Dimitar, Aminian, Adel, Garducci, Stefano, Merkely, Bela, Routledge, Helen, Ando, Kenji, Diaz Fernandez, Josè Francisco, Cuisset, Thomas, Nesa Malik, Fazila Tun, Halabi, Majdi, Belle, Loic, Din, Jehangir, Beygui, Farzin, Abhyankar, Atul, Reczuch, Krzysztof, Pedrazzini, Giovanni, Heg, Dik, Vranckx, Pascal, MASTER DAPT Investigators, Cardiology, ACS - Heart failure & arrhythmias, Valgimigli, M, Smits, PC, Frigoli, E, Bongiovanni, D, Tijssen, J, Hovasse, T, Mafragi, A, Ruifrok, WT, Karageorgiev, D, Aminian, A, Garducci, S, Merkely, B, Routledge, H, Ando, K, Fernandez, JFD, Cuisset, T, Malik, FTN, Halabi, M, Belle, L, Din, J, Beygui, F, Abhyankar, A, Reczuch, K, Pedrazzini, G, Heg, D, and VRANCKX, Pascal

Subjects
animal structures, Aspirin, Myocardial Infarction, Hemorrhage, Percutaneous coronary intervention, Stroke, Treatment Outcome, Complex intervention, Dual antiplatelet therapy, Humans, Drug Therapy, Combination, Acute Coronary Syndrome, High bleeding risk, 610 Medizin und Gesundheit, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors
Abstract

Aim To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). Methods and results In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69–1.52, and HR: 1.24, 95% CI: 0.79–1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71–1.15, and HR: 0.91, 95% CI: 0.69–1.21; Pinteraction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42–0.98, and HR: 0.70; 95% CI: 0.55–0.89; Pinteraction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. Conclusion In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity. Clinical Trial Registration This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.

Published
2022

27. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial

Author

Cayla, Guillaume, Cuisset, Thomas, Silvain, Johanne, Leclercq, Florence, Manzo-Silberman, Stephane, Saint-Etienne, Christophe, Delarche, Nicolas, Bellemain-Appaix, Anne, Range, Grégoire, El Mahmoud, Rami, Carrié, Didier, Belle, Loic, Souteyrand, Geraud, Aubry, Pierre, Sabouret, Pierre, du Fretay, Xavier Halna, Beygui, Farzin, Bonnet, Jean-Louis, Lattuca, Benoit, Pouillot, Christophe, Varenne, Olivier, Boueri, Ziad, Van Belle, Eric, Henry, Patrick, Motreff, Pascal, Elhadad, Simon, Salem, Joe-Elie, Abtan, Jérémie, Rousseau, Hélène, Collet, Jean-Philippe, Vicaut, Eric, and Montalescot, Gilles

Published
2016
Full Text
View/download PDF

31. European Resuscitation Council Guidelines for Resuscitation 2015: Section 1. Executive summary

Author

Khalifa, Gamal Eldin Abbas, Alfonzo, Annette, Arntz, Hans-Richard, Askitopoulou, Helen, Bellou, Abdelouahab, Beygui, Farzin, Biarent, Dominique, Bingham, Robert, Bierens, Joost J.L.M., Böttiger, Bernd W., Bossaert, Leo L., Brattebø, Guttorm, Brugger, Hermann, Bruinenberg, Jos, Cariou, Alain, Carli, Pierre, Cassan, Pascal, Castrén, Maaret, Chalkias, Athanasios F., Conaghan, Patricia, Deakin, Charles D., De Buck, Emmy D.J., Dunning, Joel, De Vries, Wiebe, Evans, Thomas R., Eich, Christoph, Gräsner, Jan-Thorsten, Greif, Robert, Hafner, Christina M., Handley, Anthony J., Haywood, Kirstie L., Hunyadi-Antičević, Silvija, Koster, Rudolph W., Lippert, Anne, Lockey, David J., Lockey, Andrew S., López-Herce, Jesús, Lott, Carsten, Maconochie, Ian K., Mentzelopoulos, Spyros D., Meyran, Daniel, Monsieurs, Koenraad G., Nikolaou, Nikolaos I., Nolan, Jerry P., Olasveengen, Theresa, Paal, Peter, Pellis, Tommaso, Perkins, Gavin D., Rajka, Thomas, Raffay, Violetta I., Ristagno, Giuseppe, Rodríguez-Núñez, Antonio, Roehr, Charles Christoph, Rüdiger, Mario, Sandroni, Claudio, Schunder-Tatzber, Susanne, Singletary, Eunice M., Skrifvars, Markus B., Smith, Gary B., Smyth, Michael A., Soar, Jasmeet, Thies, Karl-Christian, Trevisanuto, Daniele, Truhlář, Anatolij, Vandekerckhove, Philippe G., de Voorde, Patrick Van, Sunde, Kjetil, Urlesberger, Berndt, Wenzel, Volker, Wyllie, Jonathan, Xanthos, Theodoros T., and Zideman, David A.

Published
2015
Full Text
View/download PDF

32. Part 5: Acute coronary syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations

Author

Ali, Abdulaziz S., Ching, Chi Keong, Longeway, Michael, Patocka, Catherine, Roule, Vincent, Salzberg, Simon, Seto, Anthony V., Nikolaou, Nikolaos I., Welsford, Michelle, Beygui, Farzin, Bossaert, Leo, Ghaemmaghami, Chris, Nonogi, Hiroshi, O’Connor, Robert E., Pichel, Daniel R., Scott, Tony, Walters, Darren L., and Woolfrey, Karen G.H.

Published
2015
Full Text
View/download PDF

34. Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure

Author

Guedeney, Paul, Farjat-Pasos, Julio I, Asslo, Gabriel, Roule, Vincent, Beygui, Farzin, Hermida, Alexis, Gabrion, Paul, Leborgne, Laurent, Houde, Christine, Huang, Florent, Lattuca, Benoit, Leclercq, Florence, Mesnier, Jules, Abtan, Jérémie, Rouanet, Stéphanie, Hammoudi, Nadjib, Collet, Jean-Philippe, Zeitouni, Michel, Silvain, Johanne, Montalescot, Gilles, and Rodés-Cabau, Josep

Abstract

Graphical AbstractPFO: patent foramen ovale ; DAPT: dual antiplatelet therapy; SAPT: single antiplatelet therapy; TIA: transient ischemic attack; MI: myocardial infarction; BARC: bleeding academic research criteria; HR: Hazard ratio; CI: confidence interval

Published
2023
Full Text
View/download PDF

38. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

Author

Collet, Jean-Philippe, Silvain, Johanne, Barthélémy, Olivier, Rangé, Grégoire, Cayla, Guillaume, Van Belle, Eric, Cuisset, Thomas, Elhadad, Simon, Schiele, François, Lhoest, Nicolas, Ohlmann, Patrick, Carrié, Didier, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A, Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Beygui, Farzin, Vicaut, Eric, and Montalescot, Gilles

Published
2014
Full Text
View/download PDF

39. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors

Author

Blanchart, Katrien, Heudel, Thibaut, Ardouin, Pierre, Lemaitre, Adrien, Briet, Clément, Bignon, Mathieu, Sabatier, Rémi, Legallois, Damien, Roule, Vincent, and Beygui, Farzin

Subjects
ST segment elevation myocardial infarction, Clinical Investigations, Platelet Glycoprotein GPIIb-IIIa Complex, glycoprotein IIb/IIIa inhibitors, acute coronary syndrome, prasugrel, ticagrelor, Percutaneous Coronary Intervention, Treatment Outcome, Humans, ST Elevation Myocardial Infarction, cardiovascular diseases, Prospective Studies, P2Y12 inhibitors, Platelet Aggregation Inhibitors
Abstract

Objectives We sought to investigate the safety and potential benefit of administrating glycoprotein IIb‐IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. Background A number of clinical trials, performed at a time when pretreatment and potent platelet inhibition was not part of routine clinical practice, have documented clinical benefits of GPI in ST‐segment elevation myocardial infarction (STEMI) patients at the cost of a higher risk of bleeding. Methods We used the data of a prospective, ongoing registry of patients admitted for STEMI in our center. For the purpose of this study only patients presenting for primary percutaneous coronary intervention and pretreated with new P2Y12 inhibitors (prasugrel or ticagrelor) were included. We compared patients who received GPI with those who did not. Results Eight hundred twenty‐four STEMI patients were included in our registry; GPIs were used in 338 patients (41%). GPI patients presented more often with cardiogenic shock and Thrombolysis in myocardial infarction (TIMI) flow grade

Published
2021

40. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY)

Author

Rangé, Grégoire, Yayehd, Komlavi, Belle, Loic, Thuaire, Christophe, Richard, Pascal, Cazaux, Pierre, Barbou, Franck, Köning, René, Chassaing, Stephan, Teiger, Emmanuel, Berthier, Romain, Decomis, Marie-Pascale, Claudel, Jean-Philippe, Delarche, Nicolas, Brunel, Philippe, De Poli, Fabien, Dupouy, Patrick, Beygui, Farzin, Albert, Franck, Collet, Jean-Philippe, and Montalescot, Gilles

Published
2014
Full Text
View/download PDF

44. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study

Author

Collet, Jean-Philippe, Hulot, Jean-Sébastien, Cuisset, Thomas, Rangé, Grégoire, Cayla, Guillaume, Van Belle, Eric, Elhadad, Simon, Rousseau, Hélène, Sabouret, Pierre, O’Connor, Stephen A., Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Barthélémy, Olivier, Beygui, Farzin, Silvain, Johanne, Vicaut, Eric, Montalescot, Gilles, and for the ARCTIC investigators

Published
2015
Full Text
View/download PDF

46. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Author

Gragnano, Felice, primary, Zwahlen, Marcel, additional, Vranckx, Pascal, additional, Heg, Dik, additional, Schmidlin, Kurt, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Gargiulo, Giuseppe, additional, McFadden, Eugene P., additional, Onuma, Yoshinobu, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Leonardi, Sergio, additional, Zurakowski, Aleksander, additional, Arrivi, Alessio, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Jüni, Peter, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Gonzalez‐Trevilla, Agustin Albarran, additional, Almeida, Manuel, additional, Neto, Pedro Alves Lemos, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, da Silva, Pedro Canas, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chang, Chun Chin, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Ferreira, Rui Cruz, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Karth, Georg Delle, additional, Dijksma, Lynn, additional, Dominici, Marcello, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath‐Ordoubadi, Farzin, additional, Ferrario, Maurizio, additional, Fontos, Geza, additional, Diaz, Jose Francisco, additional, Quintella, Edgard Freitas, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Ribeiro, Vasco Gama, additional, Garg, Scot, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Antolin, Rosa Ana Hernández, additional, Hildick‐Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Miguel, Carlos Macaya, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean‐François, additional, Moschovitis, Aris, additional, Ottesen, Michael Munndt, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz‐Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker‐Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees‐Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Peñaranda, Antonio Serra, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, Weele, Addy Ter, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova‐Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, van Meijeren, Cokky, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, Dahl, Jürgen Vom, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2022
Full Text
View/download PDF

47. Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry

Author

Beygui, Farzin, primary, Roule, Vincent, additional, Ivanes, Fabrice, additional, Dechery, Thierry, additional, Bizeau, Olivier, additional, Roussel, Laurent, additional, Dequenne, Philippe, additional, Arnould, Marc-Antoine, additional, Combaret, Nicolas, additional, Collet, Jean Philippe, additional, Commeau, Philippe, additional, Cayla, Guillaume, additional, Montalescot, Gilles, additional, Benamer, Hakim, additional, Motreff, Pascal, additional, Angoulvant, Denis, additional, Marcollet, Pierre, additional, Chassaing, Stephan, additional, Blanchart, Katrien, additional, Koning, René, additional, and Rangé, Grégoire, additional

Published
2022
Full Text
View/download PDF

50. Clinical outcomes of the proximal optimisation technique (POT) in bifurcation stenting: Impact of proximal optimisation technique

Author

Chevalier, Bernard, Mamas, Mamas, Hovasse, Thomas, Rashid, Muhammad, Gómez-Hospital, Joan, Pan, Manuel, Witkowski, Adam, Crowley, James, Aminian, Adel, McDonald, John, Beygui, Farzin, Fernandez Portales, Javier, Roguin, Ariel, and Stankovic, Goran

Subjects
Percutaneous Coronary Intervention, Treatment Outcome, Clinical Research, Humans, Stents, Coronary Artery Disease, Registries, Coronary Angiography
Abstract

BACKGROUND: Optimal deployment of coronary stents in a bifurcation lesion remains a matter of debate. AIMS: We sought to capture the daily practice of bifurcation stenting by means of a worldwide registry and to investigate how post-implantation deployment techniques influence clinical outcomes. METHODS: Data from the e-ULTIMASTER registry were used to perform an analysis of 4,395 patients undergoing percutaneous coronary intervention for bifurcation lesions. Inverse probability of treatment weights (IPTW) propensity score methodology was used to adjust for any baseline differences. The primary outcome of interest was target lesion failure (TLF) at one year (follow-up rate 96.2%). RESULTS: The global one-year TLF rate was low (5.1%). The proximal optimisation technique (POT) was used in 33.9% of cases and was associated with a reduction in the adjusted TLF rate (4.0% [95% confidence interval: 3.0-5.1%] vs 6.0% [5.1-6.9%], p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results